A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB007839 Following Multiple Oral Doses in Patients With Solid Tumors.
Phase of Trial: Phase I/II
Latest Information Update: 20 Jan 2012
At a glance
- Drugs Aderbasib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 26 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.